Retatrutide Side Effects

What we know about retatrutide's side effects comes from its clinical trials — primarily the Phase 2 studies (Jastreboff et al., 2023, published in the New England Journal of Medicine; Rosenstock et al., 2023, published in The Lancet) and the Phase 3 TRIUMPH program. Retatrutide is not approved, so there is no real-world post-marketing safety data yet, and long-term safety beyond roughly a year of exposure has not been characterized (GLP-3 Wiki).

The specific percentages below are drawn from GLP-3 Wiki's summary of the trial data; for the underlying primary sources, see the published trial papers and Lilly's trial disclosures.

The common side effects: gastrointestinal

Like other GLP-1 drugs, the most common side effects are gastrointestinal and dose-related, and they cluster during the dose-escalation (titration) period. In TRIUMPH-1:

• Nausea: 28.6% / 38.4% / 42.4% at the 4 mg / 9 mg / 12 mg doses, vs 14.8% on placebo
• Diarrhea: 25.2% / 34.1% / 32.0% vs 13.5% on placebo
• Vomiting: reported in roughly a quarter of patients at the 12 mg dose

Most GI effects were mild to moderate and concentrated during the dose-escalation window. Slower titration and a lower starting dose meaningfully reduced the rate (GLP-3 Wiki).

The novel signal: skin sensation (dysesthesia/hyperesthesia)

Retatrutide showed a side effect not seen with older GLP-1 drugs: dysesthesia — abnormal skin sensations such as burning, tingling, or numbness. In Phase 2, "cutaneous hyperesthesia" (skin sensitivity) appeared in about 7% of retatrutide patients vs 1% on placebo, rising to roughly 13% at the 12 mg dose. In TRIUMPH-4, dysesthesia was reported in about 20.9% at 12 mg. In the reported data these events were mostly not severe or discontinuation-driving, but the signal is being watched as Phase 3 matures (GLP-3 Wiki).

The heart-rate signal

Retatrutide produced a dose-dependent increase in resting heart rate of roughly 6.7 beats per minute at the 12 mg dose, peaking around week 24 and then partially declining. This is a known class effect of GLP-1 receptor agonists, but retatrutide's glucagon receptor activity may amplify it, which has raised questions among cardiologists about myocardial oxygen demand. Phase 2 trials reported no cardiovascular events (heart attack, stroke, or hospitalization for heart failure) attributed to the drug during the observation period — but those trials were short and excluded people with recent cardiovascular events, so they were not powered to detect cardiovascular outcomes (GLP-3 Wiki).

The long-term cardiovascular safety question is being answered by TRIUMPH-Outcomes, retatrutide's dedicated cardiovascular and renal outcomes trial, expected to complete in 2026.

Other class-level risks

As with the broader GLP-1 class, retatrutide carries precautionary signals for:

• Pancreatitis — no confirmed cases in Phase 2, but a known class concern; people with a history of pancreatitis warrant caution.
• Gallbladder disease — a known GLP-1 class risk.
• Injection-site reactions — e.g., redness or mild pain.
• Liver enzyme elevations — ALT/AST above 3x the upper limit of normal occurred in about 1.2% of participants in Phase 2.

How serious were the side effects in trials?

In Phase 2, serious adverse events were reported in roughly 4% of participants in both the retatrutide and placebo groups — meaning no clear excess of serious harm was attributed to the drug in the short term. One death occurred during Phase 2 (in a 4 mg arm, among 337 participants). No pancreatitis and no drug-related cardiovascular events were reported during the Phase 2 observation window (GLP-3 Wiki).

When to contact a clinician (red flags)

Seek prompt medical attention if you experience:

• Severe or persistent abdominal pain (especially pain radiating to the back, which can suggest pancreatitis)
• Unexplained rapid heart rate or palpitations
• Signs of dehydration (dizziness, reduced urine output, extreme thirst) following vomiting or diarrhea
• Severe vomiting that prevents keeping fluids down
• Any allergic reaction (rash, swelling, difficulty breathing)
• Persistent or distressing skin sensations

The bottom line

Retatrutide's side-effect profile so far looks like a more potent GLP-1 — heavy on gastrointestinal effects during titration, with two genuinely new signals (skin sensation and a slightly larger heart-rate bump) that are still being characterized. But the key caveat is duration: these findings come from short, screened trials, and long-term safety is not yet established. Retatrutide remains investigational and is not FDA-approved (FDA).

Retawiz provides educational information only and is not medical advice. Side-effect figures are from publicly available trial data; individual experiences vary. Retatrutide is investigational and not FDA-approved. Retawiz does not sell, source, or recommend any medication. Consult a licensed clinician for any medical decision.